Latest Funds Under Management News

Charter Hall (ASX: CHC) has won a $1.2 billion diversified direct property mandate from an existing institutional client, reinforcing its growth trajectory in funds under management and showcasing its sector expertise across Australia.

Elanor Investors Group has completed documentation for a $125 million balance sheet recapitalisation with Rockworth Capital Partners, preparing to release HY26 financial results and advance leadership renewal and rebranding initiatives.

Microequities Asset Management Group reports a significant decline in Funds Under Management due to global market volatility but maintains strong profitability and liquidity.

Betashares Capital Ltd has announced the Distribution Reinvestment Plan (DRP) issue prices for 30 of its ETFs for the March 2026 distribution period, with elections due by 7 April and unit issuance scheduled for 20 April.

Count Limited has announced a strategic acquisition of Oracle Group, significantly expanding its financial advice and wealth management footprint across Australia. The deal is backed by a $40.9 million equity raising to support growth ambitions.

360 Capital FM Limited has activated the Distribution Reinvestment Plan (DRP) for 360 Capital REIT for the March 2026 quarter, offering securityholders a cost-effective way to reinvest distributions into additional securities.

Neometals Ltd has released a positive scoping study for its Ironclad gold deposit at the Barrambie Gold Project, outlining a rapid production pathway with potential output of up to 11,000 ounces of gold within a year.

Cann Group Limited has raised $750,000 through a convertible note agreement with Obsidian Global, aiming to strengthen its working capital and move towards EBITDA positivity.

GQG Partners reported a rise in funds under management to USD 172.9 billion as of February 28, 2026, buoyed by strong investment performance that offset net client withdrawals.

Elanor Investors Group reported a $57 million statutory loss for FY25 but is progressing a $125 million recapitalisation with Rockworth Capital Partners to stabilise its balance sheet amid ongoing financial challenges.

Recce Pharmaceuticals reported a doubling of its net loss for the half-year ended December 2025 amid significant progress in its anti-infective drug development and a substantial funding boost. The company is advancing Phase 3 trials and expanding its patent portfolio while managing financial pressures.

HALO Technologies reports a strategic pivot towards APAC growth and a UK business model overhaul, alongside a 16% revenue decline and increased net loss in FY25.